CTLA4 and head and neck cancer: As shown by Ruffin et al., melanoma patients who did not respond to standard of care immunotherapy i.e. anti-PD1 and/or anti-CTLA4 had significantly more naive B cells than responders, which indicates that driving naive TIL-B cells towards activated and germinal center phenotypes could be one way to complement current immunotherapeutic strategies also in head and neck cancer (41).